LCH-II Langerhans cell histiocytosis: treatment protocol of the second international study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN57679341

Enrollment

193

Registered

2001-07-01

Start date

2002-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhans cell histiocytosis Haematological Disorders Certain diseases involving lymphoreticular tissue and reticulohistiocytic system

Interventions

Risk group patients are randomised to either: 1. Arm A: Initial treatment with oral prednisone and vinblastine. Continuation treatment with oral 6-mercaptopurine plus pulses of oral prednisone and vi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Definitive diagnosis of Langerhans cell histiocytosis 2. Aged under 18 years with involvement of haematopetic system, liver, lungs or spleen or aged under 2 years 3. No prior treatment for Langerhans cell histiocytosis

Exclusion criteria

Exclusion criteria: Does not comply with above criteria

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Austria, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 6, 2026